v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:        
Net loss $ (6,202,164) $ (151,677) $ (17,087,453) $ (9,941,284)
Adjustment to reconcile net loss to net cash used in operating activities:        
Stock-based compensation 611,502 20,422 472,263 5,428
Non-cash interest earned on short-term investments (4,324)    
Change in fair value of SAFE liability     833,328
Non-cash license expense – related parties     2,900,000
Non-cash interest expense – related party 50,785 42,268
Non-cash interest earned on promissory notes – related parties (59,178) (65,096)
Changes in assets and liabilities:        
Tax incentive receivable (933,250)    
Prepaid expenses 198,464 (834,479)
Accounts payable 2,165,548 260,613
Accrued expenses and other current liabilities 3,467,666 1,437,499 1,522,983
Net cash used in operating activities (704,951) (131,255) (12,041,057) (8,412,873)
Cash flows from investing activities:        
Purchase of short-term investments (10,063,562)    
Net cash provided by investing activities (10,063,562)    
Cash flows from financing activities:        
Proceeds from capital contribution by stockholder     7,450,000 8,711,966
Proceeds from issuance of SAFE instruments     7,500,000
Proceeds from issuance of common stock 20,000,000 32,965,500
Payment transaction costs     (4,257,861)
Cash provided to stockholder in exchange for promissory note     (4,000,000)
Reimbursement of equity issuance costs to stockholder     (5,802)
Net cash provided by investing activities 20,000,000 39,657,639 8,706,164
Net increase in cash and cash equivalents 9,231,487 (131,255) 27,616,582 293,291
Cash and cash equivalents at beginning of year 28,417,310 800,728 800,728 507,437
Cash and cash equivalents at end of year 37,648,797 669,473 28,417,310 800,728
Supplemental disclosure of cash flow information:        
Issuance of common stock upon conversion of SAFE instruments     12,645,824
Issuance of common stock upon conversion of convertible preferred shares     5,466,925
Issuance of promissory notes to related parties for licensing     2,900,000
Stock issuance costs included in accounts payable and accrued expenses 1,506,000    
Interest receivable on promissory note issued to stockholder $ 59,178 65,096
Issuance of promissory notes to settle accrued expenses     1,280,036
Assumption of promissory notes and related accrued interest by stockholder     $ 5,426,120